Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Abnormal Proliferation02:23

Abnormal Proliferation

4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

4.9K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.9K
T Cell Types and Functions01:24

T Cell Types and Functions

3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives.

Immuno-oncology technology·2025
Same author

Cre-lox: Target Sensitivity Matters.

Immunity·2019
Same author

Pathophysiological role of respiratory dysbiosis in hospital-acquired pneumonia.

The Lancet. Respiratory medicine·2019
Same author

Differences in prognosis of Siewert II and III oesophagogastric junction cancers are determined by the baseline tumour staging but not its anatomical location.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2016
Same author

NIK promotes tissue destruction independently of the alternative NF-κB pathway through TNFR1/RIP1-induced apoptosis.

Cell death and differentiation·2015
Same author

PTPN2 controls differentiation of CD4⁺ T cells and limits intestinal inflammation and intestinal dysbiosis.

Mucosal immunology·2014

Related Experiment Video

Updated: Apr 24, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K

New insights into IL-12-mediated tumor suppression.

S Tugues1, S H Burkhard1, I Ohs1

  • 1Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.

Cell Death and Differentiation
|September 6, 2014
PubMed
Summary

Interleukin-12 (IL-12) shows potent antitumor activity in preclinical models but faces challenges in clinical translation due to toxicity and limited efficacy. Strategies are needed to harness IL-12's potential while mitigating adverse effects.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.8K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K

Related Experiment Videos

Last Updated: Apr 24, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.8K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.8K
Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.8K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Interleukin-12 (IL-12) is a potent cytokine demonstrating significant antitumor activity in preclinical cancer models.
  • IL-12 bridges innate and adaptive immunity by influencing immune cells within the tumor microenvironment.
  • Despite promising preclinical data, clinical translation of IL-12 therapy has been hindered by limited efficacy and dose-limiting toxicities.

Purpose of the Study:

  • To review the therapeutic effects of IL-12 from preclinical research to clinical trials.
  • To highlight strategies aimed at optimizing IL-12 antitumor activity.
  • To discuss methods for minimizing adverse effects associated with IL-12 treatment.

Main Methods:

  • Review of preclinical studies investigating IL-12 in various tumor models.
  • Analysis of clinical trial data assessing IL-12 efficacy and safety.
  • Discussion of emerging strategies for IL-12-based cancer immunotherapy.

Main Results:

  • IL-12 consistently demonstrates robust antitumor responses in preclinical settings.
  • Clinical trials have shown limited success in achieving sustained antitumor effects with IL-12 therapy.
  • Significant toxic side effects have been reported in patients treated with IL-12.

Conclusions:

  • IL-12 possesses considerable potential as an anticancer agent, evidenced by extensive preclinical success.
  • Overcoming clinical challenges requires innovative therapeutic strategies to improve efficacy and tolerability.
  • Future research should focus on developing safer and more effective IL-12-based immunotherapies for cancer treatment.